A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag

Abstract Avatrombopag is a next-generation thrombopoietin receptor agonist approved for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo surgery and thrombocytopenia in patients with chronic immune thrombocytopenia. However, realistic data on its post-mar...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhong Xue, Maohua Chen, Mingzuo Wang, Fan Zhang, Zhaoshuo Chen
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Avatrombopag 
FAERS 
Adverse event 
Thrombocytopenia 
Chronic liver disease 
Online Access:https://doi.org/10.1038/s41598-024-80067-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-80067-0

Similar Items